The US Food and Drug Administration (FDA) has approved Abbott’s next-generation Xience Prime everolimus-eluting coronary stent system, used to treat coronary artery disease.
The Xience Prime uses cobalt chromium technology and features a ‘peak-to-valley’ design that gives the stent longitudinal strength and stability.
The stent uses a drug and biocompatible polymer similar to that of the Xience V everolimus-eluting coronary stent system.
The approval is backed by results from a prospective, open-label Spirit Prime clinical trial, which reported the Xience Prime met its primary endpoint, with low rates of target lesion failure after one year.
Xience Prime is available in the US, Europe, the Middle East and most of Asia.
Share this article
